RBC Capital analyst Gregory Renza maintains ADC Therapeutics (NYSE:ADCT) with a Outperform and lowers the price target from $30 to $29.
August 9, 7:09 AM
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.91) by 19.78 percent. This is a 4.29 percent decrease over losses of $(0.70) per share from the
July 8, 4:02 PM
ADC Therapeutics SA (NYSE: ADCT) shares are trading higher by 11.56% to $10.23 Friday afternoon after the company entered into an exclusive license agreement with Swedish Orphan Biovitrum for the development and commercialization of ZYNLONTA.
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
July 8, 8:19 AM
Here's a roundup of top developments in the biotech space over the last 24 hours:
July 8, 7:20 AM
ADC Therapeutics SA (NYSE:ADCT) has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (OTC:BIOVF) for the development and commercialization of…
ADC Therapeutics Announced Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA in Europe and Select International Territories; ADC Therapeutics is Eligible to Receive Up to $435M, Including Milestones
July 8, 4:50 AM
ADC Therapeutics SA (NYSE: ADCT) today announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the United States, greater China, Singapore and Japan.
June 13, 2:43 PM
ADC Therapeutics SA (NYSE:ADCT) presented updated efficacy and safety results from the Phase 2 trial of camidanlumab tesirine (Cami, formerly ADCT-301)…